Milan-based Axxam celebrates its 25th anniversary as a pioneer in the field of life sciences, providing early discovery services and solutions to support innovation in pharmaceuticals, biotechnology, agrochemicals and animal health.
As a contract research organization, it remains steadfast in its mission — to harness biology to empower discovery and transform ideas into actionable breakthroughs that improve human health and daily life.
Through Axxsense, its proprietary research platform, Axxam shares its expertise beyond drug discovery by developing new bioactive compounds for various industries, including food and beverages, nutraceuticals, cosmetics, flavors and fragrances, pet food and perfumery.
To stay ahead of the industry, Axxam adopts the latest technology. It uses artificial intelligence and machine learning, among other technologies, for target identification, compound design and the creation of advanced nonanimal disease models, including cells derived from induced pluripotent stem cells.
“Axxam is a biology powerhouse positioned in the ‘target-to-lead’ segment within the R&D (research and development) value chain operating under ISO (International Organization for Standardization) quality standards. We aspire to become a global leader in early drug discovery to better serve the pharmaceutical industry,” CEO Ciriaco Maraschiello said.
“Axxam provides solutions to reduce the translational gap by incorporating generative artificial intelligence and investing in NAMs (new approach methods). Our mission is to enhance confidence in the target and the molecule at early drug discovery stages, maximizing the probability of success in progressing to later drug development stages,” Maraschiello added.
He also stressed that Axxam’s passion for innovation mirrored Japan’s openness to creativity and its commitment to science, sustainability and meaningful progress.